SCHEMBL19652201

SCHEMBL19652201

CC(C)C(=O)N1CCC(C(=O)N(C)C)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CHRNB2 P17787 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA4 P43681 1/20 0.39
CHRNB3 Q05901 1/20 0.39
CHRNA6 Q15825 1/20 0.39
CYP2D6 P10635 1/20 0.38
DPP4 P27487 2/20 0.37
NPY5R Q15761 1/20 0.37
PRMT5 O14744 2/20 0.37
WDR77 Q9BQA1 2/20 0.37
KCNH2 Q12809 1/20 0.36
DPP8 Q6V1X1 1/20 0.36
DPP9 Q86TI2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25912481 0.89 MEN1 (0.45) MEN1KMT2ASMN1; SMN2GAAMAPT
SCHEMBL25895223 0.86 MEN1 (0.41) MEN1KMT2ASMN1; SMN2GAAMAPT
SCHEMBL23342773 0.83 GAA (0.46) MEN1KMT2ASMN1; SMN2GAAMAPT
SCHEMBL25919918 0.80 BCHE (0.47) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL16643864 0.79 MEN1 (0.50) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL322431 0.79 LMNA (0.50) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL12531876 0.79 MEN1 (0.46) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL12436051 0.79 KDM4E (0.43) MEN1KMT2ASMN1; SMN2GAAMAPT
SCHEMBL4546641 0.77 L3MBTL3 (0.53) MEN1KMT2ASMN1; SMN2ALDH1A1CHRNB2
SCHEMBL4546658 0.77 GAA (0.53) MEN1KMT2ASMN1; SMN2GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10258603-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-04-16 US disclosed
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10258603-B2 Therapeutic compounds and uses thereof BRD4, BRDT, BRD3 MEN1 1364/4885KMT2A 165/4885SMN1; SMN2 1221/4885
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF BRD4, BRDT, BRD3 MEN1 1364/4885KMT2A 165/4885SMN1; SMN2 1221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.